This is a limited company view. Sign up for a Free Trial to see everything.

Admittance Technologies is committed to improving the quality of life of patients with heart disease through innovative electrical engineering solutions. We have developed a novel and proprietary volume measurement technology called CardioVol(tm). Our goal is to reduce heart failure hospitalizations through the integration of CardioVol(tm) into implantable devices that connect with shocking coil leads, allowing these devices to provide real time ventricular blood volume data. CardioVol(tm) enabled devices operate at extremely low power and can monitor preload directly (via End Diastolic Volume), allowing physicians and patients to monitor actionable hemodynamic data without a separate implant. These data can be used to adjust medication (telemedicine) and possibly prevent acute heart failure hospitalizations.

B2B
Biotechnology
Healthcare
Medical Devices
Medical Diagnostics
Pharmaceuticals

Overview

Location

Austin

Founded

2010

Employees

3

Stage

Late

Total funding

$2M

Last funding

5 years ago

Acquisitions

0

Growth score

-35

Mindshare score

-37

Scoring

Deals

$2.0M Venture

The Texas Emerging Technology Fund

Jan 19, 2013

Employee Growth

Use Admittance Technologies's historical employee count to better understand their growth and spending over time.

Unlock with a Free Trial

Mobile

Use Admittance Technologies's mobile downloads and app ranks to evaluate the performance of their mobile apps.

Unlock with a Free Trial

Key People

Chief Executive Officer and Director

Similar Companies

PneumaCare

PneumaCare makes innovative technology for non invasive respiratory diagnosis and monitoring.
Unknown|7 employees

Gain context with Mattermark Salesforce Enrichment

Find out how

Notes